A possible future test to differentiate between risk for aggressive and indolent forms of prostate cancer

A new paper by an  international group of researchers from several different centers has maybe identified a new way to differentiate accurately between indolent and aggressive forms of prostate cancer at time of initial diagnosis. … READ MORE …

Just how important is this scientific paper?

The most frequent alteration in the prostate oncogenome is loss of chromosome (chr) 8p21 that has been associated with loss of NKX3.1 homeobox gene.
… READ MORE …

Can TMPRSS2-ERG gene expression predict low response to taxane therapy?

Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …

Liquid biopsies and CTC assays — the scientific progress continues

A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …

The role of liquid biopsies in management of advanced prostate cancer

A newly published paper in Science Translational Medicine has added to our understanding of the future potential of liquid biopsies (e.g., blood, plasma, and similar samples) in the management of progressive forms of prostate cancer. … READ MORE …

“Basket” studies — another new class of clinical trial

Although it has no immediate relevance to the treatment of prostate cancer, it is worth noting that the results of the very first, completed and published “basket” type of clinical trial appear in this week’s issue of the New England Journal of Medicine (NEJM). … READ MORE …

How many “different” types of prostate cancer are there?

This, of course, is a rhetorical question. We really have no good idea how many “different” types of prostate cancer there are. And so what we are really dealing with here is how we are going to sub-classify prostate cancers in the future in order to treat them most appropriately at the earliest relevant stage of development. … READ MORE …